“…13–22 For the latter, permissive catalysts involved in late-stage NP tailoring modifications (acylation, alkylation, glycosylation, oxidation) have been particularly enabling in NP core scaffold diversification. 5,15,23–30 The demonstrated impact of glycosylation within this context is diverse and includes influencing NP or small-molecule drug potency, mechanism, pharmacodynamics, pharmacokinetics, and ADME properties 29–39 where the advent of permissive chemoenzymatic strategies complement and/or circumvent key limitations of conventional chemical glycosylation as a medicinal chemistry tool. 29,40–51 Such chemoenzymatic strategies have benefited from the development of donor/acceptor permissive glycosyltransferases via directed evolution and a corresponding screening platform enabled by the use of simple activated glycoside donors that drive the equilibrium of glycosyltransferase-catalyzed reactions toward product formation and provide real-time indicators of sugar-nucleotide utilization in parallel (Figure 1).…”